• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    11/14/24 6:58:27 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALXO alert in real time by email
    SC 13G/A 1 ea022116103-13ga1viv9_alxon.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    ALX Oncology Holdings Inc.

     

    (Name of Issuer)

     

    Common stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    00166B105

     

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 00166B105
    1 NAMES OF REPORTING PERSONS  
    Vivo Capital Fund IX, L.P.  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
    (a)    ☐
    (b)    ☒
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5 SOLE VOTING POWER
    1,813,864(1)
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER

    1,813,864(1)

    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,813,864(1)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    3.4% (2)
    12 TYPE OF REPORTING PERSON  (See Instructions)
    PN

     

    (1)       The shares of common stock, par value $0.001 per share (the “Common Stock”) of ALX Oncology Holdings Inc. (the “Issuer”) are held of record by Vivo Capital Fund IX, L.P, as of November 8, 2024.Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

     

    (2)Based on 52,743,104 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 7, 2024.

     

    2

     

     

    CUSIP No. 00166B105
    1 NAMES OF REPORTING PERSONS  

    Vivo Capital IX, LLC

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
    (a)    ☐
    (b)    ☒
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5 SOLE VOTING POWER

    1,813,864(1)

    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER

    1,813,864(1)

    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,813,864(1)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    3.4 % (2)
    12 TYPE OF REPORTING PERSON  (See Instructions)
    OO

     

    (1)The shares of Common Stock of the Issuer are held of record by Vivo Capital Fund IX, L.P. as of November 8, 2024. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

     

    (2)Based on 52,743,104 shares of Common Stock outstanding as of October 31, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 7, 2024.

     

    3

     

     

    CUSIP No. 00166B105
    1 NAMES OF REPORTING PERSONS  
    Vivo Opportunity Fund Holdings, L.P.  
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
    (a)    ☐
    (b)    ☒
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5 SOLE VOTING POWER

    0 (1)

    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER

    0 (1)

    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0 (1)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0 % (2)

    12 TYPE OF REPORTING PERSON  (See Instructions)
    PN

     

    4

     

     

    CUSIP No. 00166B105
    1 NAMES OF REPORTING PERSONS  

    Vivo Opportunity, LLC

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)  
    (a)    ☐
    (b)    ☒
    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5 SOLE VOTING POWER

    0 (1)

    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER

    0 (1)

    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0 (1)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
    ☐
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0 % (2)
    12 TYPE OF REPORTING PERSON  (See Instructions)
    OO

     

    5

     

     

    Item 1. (a)Name of Issuer:

     

    ALX Oncology Holdings Inc.

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    323 Allerton Avenue

     

    South San Francisco, California 94080

     

    Item 2. (a)Name of Person Filing:

     

    Vivo Capital Fund IX, L.P. and its General Partner Vivo Capital IX, LLC

     

    Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    192 Lytton Avenue, Palo Alto, CA 94301

     

    (c)Citizenship:

     

    Vivo Capital Fund IX, L.P. is a Delaware limited partnership.

     

    Vivo Capital IX, LLC is a Delaware limited liability company.

     

    Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership

     

    Vivo Opportunity, LLC is a Delaware limited liability company.

     

    (d)Title of Class of Securities:

     

    Common stock, par value $0.001 per share

     

    (e)CUSIP Number:

     

    00166B105

     

    Item 3.If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a)☐ Broker or dealer registered under Section 15 of the Act.
    (b)☐ Bank as defined in Section 3(a)(6) of the Act.
    (c)☐ Insurance company as defined in Section 3(a)(19) of the Act.
    (d)☐ Investment company registered under Section 8 of the Investment Company Act of 1940.
    (e)☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)☐ A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);
    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
    (i)☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
    (j)☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
    (k)☐ Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

     

    Not Applicable.

     

    6

     

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    The 1,813,864 shares of Common Stock are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.

     

    (b)Percent of class:

     

    Vivo Capital Fund IX, L.P. 3.4 %

     

    Vivo Capital IX, LLC: 3.4%

     

    Vivo Opportunity Fund Holdings, L.P.: 0%

     

    Vivo Opportunity, LLC: 0%

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    Vivo Capital Fund IX, L.P.: 1,813,864 shares

     

    Vivo Capital IX, LLC: 1,813,864 shares

     

    Vivo Opportunity Fund Holdings, L.P.: 0 share

     

    Vivo Opportunity, LLC: 0 share

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    Vivo Capital Fund IX, L.P.: 1,813,864 shares

     

    Vivo Capital IX, LLC: 1,813,864 shares

     

    Vivo Opportunity Fund Holdings, L.P.: 0 share

     

    Vivo Opportunity, LLC: 0 share

     

    (iv)Shared power to dispose of or to direct the disposition of: 0

     

    7

     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

     

    8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        Vivo Capital Fund IX, L.P.
         
        By: Vivo Capital IX, LLC, its General Partner
         
        November 14, 2024
        (Date)
         
        /s/ Frank Kung
        (Signature)
         
        Managing Member
        (Title)
         
        Vivo Capital IX, LLC
         
        November 14, 2024
        (Date)
         
        /s/ Frank Kung
        (Signature)
         
        Managing Member
        (Title)
         
        Vivo Opportunity Fund Holdings, L.P.
         
        By: Vivo Opportunity, LLC, its General Partner
         
        November 14, 2024
        (Date)
         
        /s/ Kevin Dai
        (Signature)
         
        Managing Member
        (Title)
         
        Vivo Opportunity, LLC
         
        November 14, 2024
        (Date)
         
        /s/ Kevin Dai
        (Signature)
         
        Managing Member
        (Title)

     

    9

     

     

    EXHIBIT INDEX

     

    Exhibit    
    99.1   Joint Filing Statement

     

    10

     

    Get the next $ALXO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALXO

    DatePrice TargetRatingAnalyst
    3/6/2025$2.00 → $3.00Hold → Buy
    Jefferies
    12/19/2024$12.00 → $2.00Buy → Hold
    Jefferies
    3/8/2024$10.00 → $14.00Buy → Hold
    Stifel
    12/8/2023$8.00 → $18.00Hold → Buy
    Jefferies
    3/1/2022$60.00 → $36.00Buy
    Stifel
    12/22/2021$65.00 → $25.00Buy → Hold
    Jefferies
    9/30/2021$106.00Buy
    Stifel
    More analyst ratings

    $ALXO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows: Format: Fireside Chat Date: Thursday, June 5, 2025Time: 1:25 PM ETLocation: New York, NYWebcast link: Available here The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology's website at www.alxoncology.com under the Events section of the Even

      5/30/25 8:00:21 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

      - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent IND clearance from U.S. FDA, ALX2004 will enter clinical studies mid-year 2025 with initial safety data anticipated in 1H 2026 - Trials evaluating the Company's lead investigational therapy, CD47-blocker evorpacept, in breast and colorectal cancers planned to initiate in mid-2025 with multiple key inflection points from evorpacept and ALX2004 development programs anticipated in 2026 SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSW

      5/20/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

      SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration e

      5/13/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hemrajani Rekha bought $46,404 worth of shares (30,000 units at $1.55), increasing direct ownership by 1,000% to 33,000 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      12/4/24 4:17:28 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

      4/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      6/24/24 9:00:55 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      6/17/24 7:29:53 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by SVP, FINANCE AND CAO Pinto Shelly

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:29:19 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Sandler Alan B.

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:19:34 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Shantharam Harish

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:16:28 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ALX Oncology upgraded by Jefferies with a new price target

      Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $3.00 from $2.00 previously

      3/6/25 7:17:16 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology downgraded by Jefferies with a new price target

      Jefferies downgraded ALX Oncology from Buy to Hold and set a new price target of $2.00 from $12.00 previously

      12/19/24 7:28:17 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology downgraded by Stifel with a new price target

      Stifel downgraded ALX Oncology from Buy to Hold and set a new price target of $14.00 from $10.00 previously

      3/8/24 7:21:35 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Leadership Updates

    Live Leadership Updates

    See more
    • ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

      Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experienceDr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced the appointmen

      1/22/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer. "Dr. Sandler's breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives," said Jason Lettmann, Chief Executive Officer at

      11/14/24 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our team continues to make significant progress in the advancement of our evorpacept development pipeline across multiple oncology indications," said Jason Lettmann, Chief Executive Officer of ALX Oncology. "Data readouts across our Phase 1 and 2 clinical trials highlight the potential of evorpacept as a disruptive therapy in combination with anti

      8/8/24 4:05:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Financials

    Live finance-specific insights

    See more
    • ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

      SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives. ALX Oncology's lea

      5/2/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

      SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.  The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives.

      2/27/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

      Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trialGreatest benefit observed among patients with confirmed HER2-positive cancer, as demonstrated by either fresh biopsy or ctDNA HER2-expression, with confirmed ORR of 48.9% and mDOR of 15.7 months vs. 24.5% ORR and mDOR of 9.1 months in the control group, and a PFS Hazard Ratio of 0.64Company to host conference call and investor webcast today at 1:00 PM PT/4:00 PM ET SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology

      1/23/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

      SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      5/15/25 4:15:24 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

      SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      5/15/25 4:05:22 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ALX Oncology Holdings Inc.

      10-Q - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      5/8/25 4:01:21 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 7:22:54 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 6:58:27 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 3:02:41 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care